The Human Cancer Proteome Project (Cancer-HPP) is an international initiative organized by HUPO whose key objective is to decipher the human cancer proteome through a coordinated effort by cancer proteome researchers around the world. The goal is to map the entire human cancer proteome to disclose tumor biology and drive improved diagnostics and treatment of cancer.
Click here to read the 2017 Cancer-HPP report.
Cancer-HPP steering committee:
Cancer HPP partners with NCI's Clinical Proteome Tumor Analysis Consortium (CPTAC).
Major goal for the coming 5 years:
Highlights in the field of cancer proteomics:
1. Summary of B/D HPP in 2015 HUPO
2. NIH Bio-specimens
National Cancer Institute (NCI)
Specimen resource locator https://specimens.cancer.gov/
3. CPTAC publications
Zhang, H, Liu T, Zhang Z, Payne S. et al (2016) Integrated proteogenomic characterization of human high grade serous ovarian cancer. Cell. http://www.cell.com/cell/home
Mertins P, et al (2016) Proteogenomic Analysis of Human Breast Cancer Connects Genetic Alterations to Phosphorylation NetworksNature . http://www.nature.com/nature.
Zhang B, Wang J, Wang X, Zhu J, et al. (2014) Proteogenomic characterization of human colon and rectal cancer Nature 513 (7518): 382-7.
Cancer-HPP Mailing List:
Are you involved in Cancer Research? Interested in the latest initiatives of the Cancer-HPP? If so, subscribe to the Cancer-HPP mailing list to receive initiative updates, news and meeting details.
The Cancer-HPP key aims are to:
1. Characterize proteomes, proteome forms, and protein networks from different cancers and the matched non-cancers through coordinated efforts of specimen collections and data acquisitions.
2. Identify cancer-specific proteins, protein forms, or protein networks from each cancer type and cancer-type-specific proteins, protein forms, and protein networks by comparison of multiple cancer types through data deposition, sharing, and data analysis.
3. Determine the protein-specific or protein-isoform-specific changes of cancer through the correlation studies of genomic and proteomic data through the comparison to the existing genomic data or the genomic data collected from each specimen.
4. Develop targeted assays to measure protein- or protein-form-specific changes for each tumor type to support the analysis of complex biological networks or clinical specimens underlying different disease processes.
5. Disseminate assays to the discovery labs to apply the targeted assays to the specimens from discovery specimens to verify the changes from discovery phase.
6. Validate the protein, protein forms, or protein network changes in independent specimens.